110.17
1.43 (1.32%)
| 前收盘价格 | 108.74 |
| 收盘价格 | 108.62 |
| 成交量 | 2,411,030 |
| 平均成交量 (3个月) | 2,549,613 |
| 市值 | 14,308,264,960 |
| 价格/销量 (P/S) | 15.92 |
| 股市价格/股市净资产 (P/B) | 55.67 |
| 52周波幅 | |
| 利润日期 | 19 Feb 2026 |
| 营业毛利率 | -53.82% |
| 营业利益率 (TTM) | -54.33% |
| 稀释每股收益 (EPS TTM) | -3.39 |
| 季度收入增长率 (YOY) | 20.80% |
| 流动比率 (MRQ) | 4.11 |
| 营业现金流 (OCF TTM) | -272.26 M |
| 杠杆自由现金流 (LFCF TTM) | -67.71 M |
| 资产报酬率 (ROA TTM) | -18.64% |
| 股东权益报酬率 (ROE TTM) | -4,584.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 看涨 |
| Diagnostics & Research (全球的) | 看涨 | 看涨 | |
| 股票 | Guardant Health, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | -1.5 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -1.20 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.53% |
| 机构持股比例 | 97.57% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 155.00 (Leerink Partners, 40.69%) | 购买 |
| 中 | 120.00 (8.92%) | |
| 低 | 105.00 (Evercore ISI Group, -4.69%) | 保留 |
| 平均值 | 124.23 (12.76%) | |
| 总计 | 12 购买, 1 保留 | |
| 平均价格@调整类型 | 101.78 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 09 Jan 2026 | 120.00 (8.92%) | 购买 | 110.17 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (-4.69%) | 保留 | 101.87 |
| 30 Oct 2025 | 90.00 (-18.31%) | 购买 | 92.41 | |
| Guggenheim | 05 Jan 2026 | 115.00 (4.38%) | 购买 | 101.87 |
| Canaccord Genuity | 22 Dec 2025 | 125.00 (13.46%) | 购买 | 101.34 |
| 30 Oct 2025 | 100.00 (-9.23%) | 购买 | 92.41 | |
| Mizuho | 17 Dec 2025 | 120.00 (8.92%) | 购买 | 97.47 |
| Barclays | 15 Dec 2025 | 120.00 (8.92%) | 购买 | 102.67 |
| 30 Oct 2025 | 85.00 (-22.85%) | 购买 | 92.41 | |
| JP Morgan | 15 Dec 2025 | 120.00 (8.92%) | 购买 | 102.67 |
| Leerink Partners | 15 Dec 2025 | 155.00 (40.69%) | 购买 | 102.67 |
| Wells Fargo | 15 Dec 2025 | 120.00 (8.92%) | 购买 | 102.67 |
| BTIG | 12 Dec 2025 | 140.00 (27.08%) | 购买 | 102.07 |
| 30 Oct 2025 | 100.00 (-9.23%) | 购买 | 92.41 | |
| Citigroup | 11 Dec 2025 | 135.00 (22.54%) | 购买 | 101.38 |
| 30 Oct 2025 | 100.00 (-9.23%) | 购买 | 92.41 | |
| Morgan Stanley | 02 Dec 2025 | 130.00 (18.00%) | 购买 | 103.87 |
| UBS | 30 Oct 2025 | 110.00 (-0.15%) | 购买 | 92.41 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | - | - | 0 | 0 |
| MONROE TERILYN J. | - | 111.98 | -8,808 | -986,320 |
| TARIQ MUSA | - | - | 0 | 0 |
| 累积净数量 | -8,808 | |||
| 累积净值 ($) | -986,320 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 111.98 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | 董事 | 17 Jan 2026 | 执行期权 | 232 | - | - |
| MONROE TERILYN J. | 职员 | 15 Jan 2026 | 处理 (-) | 8,808 | 111.98 | 986,320 |
| MONROE TERILYN J. | 职员 | 15 Jan 2026 | 执行期权 | 17,379 | - | - |
| TARIQ MUSA | 董事 | 15 Jan 2026 | 执行期权 | 250 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合